4 Healthcare Stock Stories for a Thursday Investment Checkup

Sanofi-Aventis (NYSE:SNY): Closing price $52.42

The drug distributor Alliance Pharma reports that it now expects the bladder cancer drug ImmuCyst, manufactured by Sanofi SA’s vaccines division, to become available in the second half of next year, telling Reuters last week that it expects to begin selling the drug in the first half of 2014. Production of ImmuCyst was suspended in the middle of last year, after mold was discovered in Sanofi Pasteur’s 100-year-old manufacturing plant in Toronto. Alliance Pharma, which purchases, markets, and distributes pharmaceutical products, said that turnover in the six months ended June 30 rose by 4 percent to $34.07 million.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY

Mylan Inc. (NASDAQ: MYL): Closing price $31.44

On Thursday, Mylan confirmed that it has been sued by Aptalis concerning the filing of an abbreviated new drug application with the FDA, for Mesalamine Rectal Suppositories, 1000 mg, which is the generic version of Canasa. Mylan filed a substantially complete ANDA containing a Paragraph IV certification for this drug, and expects to be eligible for 180 days of marketing exclusivity upon final FDA clearance. The plaintiffs filed the lawsuit in the United States District Court for the District of New Jersey. For the 12 months ending March 31, 2013, Canasa had domestic sales of around $153 million, according to IMS Health.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYL

Aetna Inc. (NYSE: AET): Closing price $64.12

Aetna and the Zurich-based Swiss Life are partnering to offer Aetna’s international and domestic health care benefits and services to Swiss Life’s roster of multinational customers. Effective September 1, Aetna will join the Swiss Life Network as its partner for the United States. Swiss Life offers comprehensive international and local employee benefit packages to multinational companies via the Swiss Life Network, which is a worldwide association of 60 insurers.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AET

Celgene Corp. (NASDAQ:CELG): Closing price $134.80

Celgene’s  wholly-owned subsidiary Celgene International Sàrl, announced Thursday that its phase III study of Revlimid (lenalidomide), in combination with dexamethasone in patients who are newly diagnosed with multiple myeloma, attained its primary endpoint of progression-free survival. In the evaluation, a doublet regimen of continuous oral lenalidomide, in combination with low-dose dexamethasone, exhibited a statistically significant improvement in PFS when compared to patients receiving a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CELG

Don’t Miss: China Finds GlaxoSmithKline Employees Guilty of Bribery.